Investors lose their appetite for the obesity trade
Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
24/7 Wall St15h
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...
FierceBiotech17h
Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
IMMvention Therapeutix Enters Strategic Collaboration with Novo Nordisk to Develop Oral Therapies for Sickle Cell Disease and Other Chronic Diseases
IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...
Google DeepMind CEO says 2025's the year we start popping pills AI helped invent
Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google ...